Primary reference for these deficiencies: Parks et al., 2004. This Exelixis deletion collection was generated in an isogenic background and provides ~56% coverage of the euchromatic genome. An overview from Exelixis as of 2004 is presented in this slide presentation.
Some restrictions apply to the distribution and use of deletion lines from Exelixis. Commercial researchers must obtain a use license from Exelixis Inc. to work with these stocks.
The entry in the Basis column below indicates how the stock center updated breakpoint sequence coordinates: R5 flank = insertion flanking sequence aligned to release 5 genome assembly (per FlyBase or R. Hoskins, personal communication) R3 author statement->R5 = Parks et al. release 3 sequence coordinate mapped forward to release 5
A single entry in Basis applies to both endpoints; two values indicate the basis of left and right endpoints, respectively. Values based on R3 author statements should be treated as approximations.
Our complementation tests have shown that 10% of the stocks in the original Exelixis deletion collection did not carry the described deletion and that 77% of the stocks are deficient. The remaining 13% are unconfirmed.